Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Drug Regulation01:25

Drug Regulation

1.2K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.2K
Preclinical Development: Overview01:28

Preclinical Development: Overview

4.0K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.0K
Clinical Trials: Overview01:11

Clinical Trials: Overview

2.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.4K
Drug Control Governance: Regulatory Bodies and Their Impact01:03

Drug Control Governance: Regulatory Bodies and Their Impact

119
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
119
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

377
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
377
Drug Discovery: Overview01:26

Drug Discovery: Overview

7.1K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.1K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Real-World Evidence for Drug Approvals: Moving Toward Greater Regulatory Clarity.

Therapeutic innovation & regulatory science·2026
Same author

Prenatal stress shapes discrete responses during early recovery from repeated adult stress.

Frontiers in cellular neuroscience·2026
Same author

The Utility of Higher Pulsed Field Ablation Applications for Atrial Fibrillation Ablation.

Journal of cardiovascular electrophysiology·2026
Same author

The utility of high-frequency jet ventilation in pulsed field ablation for atrial fibrillation.

Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing·2026
Same author

Utility of Very High Output Pace-Capture Testing for Posterior Wall Isolation in Patients With Persistent Atrial Fibrillation.

Journal of cardiovascular electrophysiology·2026
Same author

Artificial intelligence-enabled sinus electrocardiograms for the detection of paroxysmal atrial fibrillation benchmarked against the CHARGE-AF score.

European heart journal. Digital health·2025
Same journal

Understanding the Added Value of Action Limits for QTL Monitoring.

Therapeutic innovation & regulatory science·2026
Same journal

Implementing Project Optimus in Oncology Dosage Optimization: Where are We Now?

Therapeutic innovation & regulatory science·2026
Same journal

Validation of the Ontario Protocol Assessment Level (OPAL) Tool for Assessing Clinical Trial Complexity and Supporting Workforce Planning in the Italian Clinical Research Context.

Therapeutic innovation & regulatory science·2026
Same journal

The Effect of Covariate Adjustment for Cox Regression in Cardiovascular Outcome Trials.

Therapeutic innovation & regulatory science·2026
Same journal

Current Status and Construction Requirements of Drug Clinical Trial Institutions in Sichuan Province in China.

Therapeutic innovation & regulatory science·2026
Same journal

The CARE Program: An Initiative of Patient-Focused Drug Development for Rare Diseases by NMPA.

Therapeutic innovation & regulatory science·2026
查看所有相关文章

相关实验视频

Updated: May 9, 2025

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
09:30

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Published on: March 17, 2023

3.2K

美国食品和药物管理局的药物开发工具资格计划是否改善了药物开发?

Felix Yang1,2, Imein Bousnina1, Anne Madej1

  • 1Genentech, A Member of the Roche Group, South San Francisco, USA.

Therapeutic innovation & regulatory science
|May 4, 2025
PubMed
概括
此摘要是机器生成的。

美国食品和药物管理局 FDA

关键词:
这就是COAA.使用上下文.美国食品药品监督管理局 FDA FDA主要/次要终点主要/次要终点资格 资格 资格 资格.

更多相关视频

Rapid Evaluation of Toxicity of Chemical Compounds Using Zebrafish Embryos
00:07

Rapid Evaluation of Toxicity of Chemical Compounds Using Zebrafish Embryos

Published on: August 25, 2019

10.5K
Small Molecule Screening and Toxicity Testing in Early-stage Zebrafish Larvae
02:52

Small Molecule Screening and Toxicity Testing in Early-stage Zebrafish Larvae

Published on: March 7, 2025

986

相关实验视频

Last Updated: May 9, 2025

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
09:30

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Published on: March 17, 2023

3.2K
Rapid Evaluation of Toxicity of Chemical Compounds Using Zebrafish Embryos
00:07

Rapid Evaluation of Toxicity of Chemical Compounds Using Zebrafish Embryos

Published on: August 25, 2019

10.5K
Small Molecule Screening and Toxicity Testing in Early-stage Zebrafish Larvae
02:52

Small Molecule Screening and Toxicity Testing in Early-stage Zebrafish Larvae

Published on: March 7, 2025

986

科学领域:

  • 药物开发 药物开发
  • 监管科学 监管科学
  • 临床结果评估 临床结果评估

背景情况:

  • 药物开发工具 (DDT) 资格计划评估用于药物开发的临床结果评估 (COA).
  • 合格的COA通过测量特定感兴趣的概念来帮助监管决策.
  • 这项分析评估了FDA的审查表现和合格COA的采用情况.

研究的目的:

  • 评估美国食品和药物管理局 (FDA) 在临床结果评估 (COA) 资格计划中审查申请的表现.
  • 评估合格的COA在药物开发中被采用和使用的程度.

主要方法:

  • 对FDA批准的总结基础 (SBA) 和COA汇编的分析.
  • 从FDA数据库中检索了资格计划 (QP) 和完整资格包 (FQP) 的提交和审查时间表.
  • 检查过的FDA COA 资格计划网站数据.

主要成果:

  • 列出了86个COA,主要是患者报告的结果 (PRO).
  • 46.7%的提交超出了目标审查时间;平均资格需要6年.
  • 只有7种COA (8.1%) 符合条件,其中3种在11种药物批准中使用,主要是作为二级终点.

结论:

  • 漫长和不可预测的审查时间表风险工具开发者和赞助商.
  • 迪迪特资格计划对将合格的COA纳入临床开发的影响有限.
  • 食品和药物管理局应该分享时间表并澄清COA的使用情况,以提高程序的实用性.